Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial

Neuro-oncology
Julia FurtnerMatthias Preusser

Abstract

Temporal muscle thickness (TMT) was described as a surrogate marker of skeletal muscle mass. This study aimed to evaluate the prognostic relevance of TMT in patients with progressive glioblastoma. TMT was analyzed on cranial MR images of 596 patients with progression of glioblastoma after radiochemotherapy enrolled in the European Organisation for Research and Treatment of Cancer 26101 trial. An optimal TMT cutoff for overall survival (OS) and progression-free survival (PFS) was defined in the training cohort (n = 260, phase II). Patients were grouped as "below" or "above" the TMT cutoff and associations with OS and PFS were tested using the Cox model adjusted for important risk factors. Findings were validated in a test cohort (n = 308, phase III). An optimal baseline TMT cutoff of 7.2 mm was obtained in the training cohort for both OS and PFS (area under the curve = 0.64). Univariate analyses estimated a hazard ratio (HR) of 0.54 (95% CI: 0.42, 0.70; P < 0.0001) for OS and an HR of 0.49 (95% CI: 0.38, 0.64; P < 0.0001) for PFS for the comparison of training cohort patients above versus below the TMT cutoff. Similar results were obtained in Cox models adjusted for important risk factors with relevance in the trial for OS (HR, ...Continue Reading

References

Sep 14, 1999·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A E TaylorC Purnell
Mar 19, 2002·BMC Geriatrics·Arnold B MitnitskiKenneth Rockwood
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Sep 21, 2006·The Journal of Clinical Endocrinology and Metabolism·Douglas Paddon-JonesArny A Ferrando
Aug 7, 2009·Journal of Cellular and Molecular Medicine·Angèle ChopardBernard J Jasmin
Aug 7, 2009·European Journal of Orthodontics·Thorsten GrünheidTheo M G J van Eijden
Feb 8, 2011·The Lancet Oncology·Kenneth FearonVickie E Baracos
May 9, 2012·Journal of Cachexia, Sarcopenia and Muscle·Josep M ArgilésFabio Penna
Oct 2, 2013·The Journal of Surgical Research·Kavitha RanganathanBenjamin Levi
Oct 29, 2013·Journal of Neurosurgery·Douglas KondziolkaRoger Stupp
Feb 7, 2014·Current Opinion in Clinical Nutrition and Metabolic Care·Filippo Giorgio Di GirolamoGianni Biolo
Feb 18, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Shlomit Strulov ShacharTomohiro F Nishijima
Jul 25, 2017·Gynecologic Oncology·Amanika KumarWilliam A Cliby
Nov 16, 2017·The New England Journal of Medicine·Wolfgang WickMartin J van den Bent
Jan 29, 2019·Geriatrics & Gerontology International·Yoko HasegawaHiromi Sanada

❮ Previous
Next ❯

Citations

Aug 8, 2020·Asia-Pacific Journal of Clinical Oncology·Havva Yesil Cinkir, Hale Colakoglu Er
Sep 16, 2020·Journal of Cancer Research and Clinical Oncology·Geon AnYong- Kil Hong
Jun 30, 2021·Clinical Neurology and Neurosurgery·Sakibul HuqDebraj Mukherjee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.